Medicare Launches $50-a-Month GLP-1 Weight Loss Program for Older Adults

A new federal program gave millions of Medicare beneficiaries their first real crack at covered weight-loss drugs on Tuesday, when the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge.

According to the CMS program page reviewed for this story, the Bridge is a short-term demonstration running from July 1, 2026, through December 31, 2027. It sits entirely outside the standard Medicare Part D benefit, which means a beneficiary's drug plan does not need to opt in, and the $50 monthly copay does not count toward the patient's Part D deductible or out-of-pocket cap.

Three drugs are covered under the Bridge when prescribed specifically for weight management: Wegovy (semaglutide, injection and tablet forms), Zepbound (tirzepatide, KwikPen formulation only), and Foundayo (orforglipron, an oral GLP-1 agent added to the list after FDA approval in April). The single-dose vial and single-dose pen versions of Zepbound are excluded, a formulation detail that could catch patients and pharmacists off guard at the counter.

Who qualifies is narrower than the headline price might suggest. Per CMS guidance, a patient must meet one of three BMI-based clinical thresholds: a BMI of 35 or higher; a BMI of 30 or higher combined with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher combined with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

Notably, patients with Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis are excluded from the Bridge entirely. As CMS explained in provider guidance, those diagnoses already qualify for GLP-1 coverage under standard Part D plans, so those patients should stay on their current coverage.

For physicians, the prior authorization process works differently than the usual Part D workflow. According to the American Medical Association's June 26 National Advocacy Update, prior authorization requests under the Bridge are processed retrospectively, after the prescription is written, through a single central processor managed by Humana, not through the patient's individual plan. Prescribers need to document the patient's diagnosis, BMI, and relevant comorbidities at the time therapy was first initiated, which matters for patients already on GLP-1 therapy who want to transition to the Bridge.

The backward-looking attestation requirement has practical stakes. As the Medicare Rights Center's coverage of the program notes, patients who started a qualifying GLP-1 drug for weight management before July 1 may be able to move to the Bridge without restarting from scratch, as long as their prescriber can document that the clinical criteria were met when therapy began.

The $50 price is a real reduction for most patients. List prices for Wegovy and Zepbound run well over $1,000 a month without assistance, and many Medicare beneficiaries have had no Part D coverage for these drugs at all when used purely for weight loss, because federal law still bars Part D plans from covering weight-loss-only indications. Changing that requires an act of Congress, as cardiologist and Yale School of Medicine professor Dr. Harlan Krumholz noted in comments to TODAY.com.

Krumholz also flagged a limitation worth naming plainly: most of the large GLP-1 clinical trials enrolled few patients over 70 or 80. The Medicare population skews older than any trial cohort, and clinicians will need to watch how these drugs perform, and what risks they carry, in patients the trials largely didn't study.

The Bridge is designed to bridge to something. CMS had planned a longer-term program called the BALANCE Model to begin in 2027, but in May CMS announced an indefinite delay of the Part D component of that model. Patients who start on the Bridge and want continuity after December 2027 will need to watch Medicare Open Enrollment this fall to see whether their plan has signed on to any successor program.

Sources cited:
- CMS Medicare GLP-1 Bridge program page (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)
- CMS Information for Providers (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers)
- American Medical Association National Advocacy Update, June 26, 2026 (https://www.ama-assn.org/health-care-advocacy/advocacy-update/june-26-2026-national-advocacy-update)
- Medicare Rights Center GLP-1 Bridge explainer (https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026)
- TODAY.com Medicare GLP-1 Bridge coverage (https://www.today.com/health/diet-fitness/medicare-glp-1-weight-loss-drugs-coverage-rcna351948)
- CMS Information for Part D Plans (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans)